SYNAGIS (palivizumab) | Parent & Caregiver Website
WEBSYNAGIS is a prescription medication that is injected (50 mg and 100 mg) in certain children to help prevent serious lung disease caused by respiratory syncytial virus (RSV). You should know that SYNAGIS is used to prevent RSV, and not to treat children who already have RSV, including children:
Synagis Vaccine: Uses, Dosage, Side Effects - Drugs.com
WEBDec 27, 2023 · Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease. Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants).
Palivizumab - Wikipedia
WEBPalivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections. It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.
Palivizumab Prophylaxis in Infants and Young Children at …
WEBJun 26, 2023 · The palivizumab package insert states “Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.” 1 In the absence of a specific definition of “high risk” by the FDA, the AAP has endeavored, since palivizumab was first licensed, to provide more precise ...
Synagis | European Medicines Agency
WEBSynagis is used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) that would require hospitalisation. It is used in the following groups of children, who are at high risk for this disease:
Synagis: Package Insert - Drugs.com
WEBSynagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season,
Synagis: Uses, Taking, Side Effects, Warnings - Medicine.com
WEBSynagis is a prescription medication that is used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in children: born prematurely (at or before 35 weeks) and who are 6 months of age or less at the beginning of RSV season, who have a chronic lung condition called bronchopulmonary dysplasia (BPD), that needed ...
Synagis - Uses, Side Effects, Interactions - MedBroadcast.com
WEBSynagis: Palivizumab belongs to the class of medications known as monoclonal antibodies. Antibodies are used to protect people against infections. Palivizumab is used to prevent serious respiratory (lung) infections caused by a …
Synagis - Side Effects, Uses, Dosage, Overdose, Pregnancy, …
WEBNov 8, 2013 · Synagis is a prescription medication used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in children younger than 24 months of age (at the start of dosing). Synagis belongs to a group of drugs called monoclonal antibodies which work by preventing the virus from replicating.
Synagis (palivizumab): Uses, Side Effects, FAQs & More - GoodRx
WEBFeb 4, 2024 · Synagis (palivizumab) is a monoclonal antibody. It's given to prevent serious respiratory syncytial virus (RSV) infections in infants and young children who are at high risk for severe illness. Synagis (palivizumab) is injected into the muscle monthly, starting right before and continuing throughout the RSV season.
Skip to content